AzTrials
AzTrials

Weight LossNCT06614543

Feasibility Testing of Plant-Based Supplemented Food Products Made With Manitoba Crop Ingredients for Weight Loss

A study testing Supplemented Food in people with Weight Loss, run by University of Manitoba at 1 site in Canada.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to advance the development of the WI/CDIC supplemented foods by evaluating the acceptance and feasibility of the supplemented food bars within the Wellness Institute's Weight Loss Clinic program (WLC) or an equivalent weight loss program in Winnipeg or the surrounding area. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Weight Loss
What is being tested?
Supplemented Food
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteCanada
Study dates
1 Nov 2026to 31 Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female, aged 18 years or above
  • Live within the province of MB
  • Ability to give written informed consent in English.
  • Enrolled in the Wellness Institute Weight Loss Clinic or an equivalent, approved weight loss program in Winnipeg or the surrounding area.

Who cannot join

  • Female participant who is pregnant, lactating or planning pregnancy during the course of the program.
  • Participants with known allergies to the supplemented food ingredients
  • Has an active eating disorder

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Kathy Cherepak, BSc contact

204-631-3834

kcherepak@sogh.mb.ca

Dr Dylan MacKay, PhD contact

204-272-3119

Dylan.Mackay@umanitoba.ca

Canada1 site
  • Seven Oaks Hospital Chronic Disease Innovation Centre

    Winnipeg, Manitoba, R2V 3M3

    Kathy Cherepak, BSc, 204-631-3834, kcherepak@sogh.mb.ca

    Dr Rebecca Mollard, PhD

Other trials in Canada

About this study

The purpose of this study is to advance the development of the WI/CDIC supplemented foods by evaluating the acceptance and feasibility of the supplemented food bars within the Wellness Institute's Weight Loss Clinic program (WLC) or an equivalent weight loss program in Winnipeg or the surrounding area. The main questions it aims to answer are:

  • To determine whether the incorporation of WI/CDIC supplemented foods into the WI weight loss clinic design is feasible.
  • To determine whether weight loss is supported by a plant-based supplemented food.
  • To assess efficacy of the supplemented food by measuring changes in lifestyle behaviours and risk factors for chronic disease compared to non-supplemented food weight loss program members.
Read more

Researchers will compare the WLC program plus supplemented food to the WLC program without the supplemented food to evaluate the implementation of the supplemented foods into the WLC.

Participants will follow their WLC program for the initial 16 weeks, and those in the intervention group will begin their supplemented food. Participants will consume one supplemented food bar each day and will record this in the product consumption log.

Read the detailed description

This is a pilot evaluation of the feasibility of incorporating the WI/CDIC supplemented food into the WI's newly designed WLC. This study will employ a mixed methods quasi-experimental approach using questionnaires and data collected over the evaluation period. Following consent, participants will be asked to fill out a set of questionnaires, to capture dietary intake, and to wear an activity monitor; to measure diet, physical activity, QOL and sleep before each study meeting. Eligible participants (n=40) will be randomized to intervention (supplemented food) or no intervention. Participants will attend two in-person study visits - one at the initiation and one at the completion of the 16-week weight loss program. Body weight, height, waist circumference, blood pressure and heart rate will be recorded at these two time points as well, as collected through the weight loss clinic program. Participants will also complete an exit questionnaire at the second visit that will include a 9-point hedonic scale to evaluate product acceptability.

Conditions
Weight Loss
Being tested
Supplemented Food
Keywords
Weight Loss Clinic, Supplemented Food
Medical subject headings
Weight Loss

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Supplemented FoodDietary supplement

    These supplemented foods provide plant-based protein, fibre and fatty acids that have been shown to have health benefits related to chronic disease.

Study groups in NCT06614543
Study groupRoleWhat they receive
The WLC program plus supplemented foodActive comparatorParticipants in weight loss clinic program will consume one supplemented food bar each day and will record this in the product consumption log.
Receives: Dietary Supplement: Supplemented Food
The WLC program onlyNo interventionParticipants in the weight loss clinic only.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Feasibility of incorporating the WI/CDIC supplemented foods into the WI weight loss clinic.

    Feasibility will be demonstrated if the following five criteria are met:

    1. Eligibility to randomization ratio is greater than 0.5, calculated as the ratio of individuals within the WI WLC program who were randomized to the trial to the number eligible to participate who were approached to participate.
    2. The percentage of participants who complete the 16-week program in the supplemented food arm is equivalent (plus or minus 10%) or greater than the standard arm.
    3. Follow up of greater than 85% of participant outcomes.
    4. Adherence to the supplemented food intervention calculated by consumption of >75% dispensed products as documented in the Product Consumption Log
    5. Product Acceptability using an Exit Questionnaire consisting of a 9-point hedonic box scale to assess mean acceptability values of 6 or greater (like at least slightly) in 75% or more of the participants.

    Measured: End of Study (Week 16)

Secondary outcomes (5)
  1. Changes in Body Weight

    Body weight will be measured in kg to the nearest 0.1 kg by an exercise professional.

    Measured: At Enrollment (Week 0) and End of Study (Week 16)

  2. Changes in Waist Circumference

    Waist circumference in cm will be measured to the nearest 0.1 cm at the umbilicus, between the last rib and iliac crest using a fibreglass tape measured by an exercise professional.

    Measured: At Enrollment (Week 0) and End of Study (Week 16)

  3. Changes in BMI

    Body Mass Index will be calculated using the formula BMI = kg/m2; where kg is the weight in kilograms and m2 is height in metres squared.

    Measured: At Enrollment (Week 0) and End of Study (Week 16)

  4. Cardiovascular Assessment

    Using the Framingham Risk Score, cardiovascular risk will be calculated based on age, HDL-C, total cholesterol, systolic blood pressure, smoking status, and diabetes status to determine the participant's 10-year risk of cardiovascular disease and identification of metabolic syndrome.

    Measured: At Enrollment (Week 0) and End of Study (Week 16)

  5. Changes is Quality of Life

    Quality of life will be measured through the SF-36 quality of life questionnaire. The SF-36 measures nine areas: physical functioning, role functioning (emotional), role functioning (physical), energy/fatigue, emotional well-being, social functioning, pain, general health, and health change. A higher score indicates greater levels of quality of life.

    Measured: At Enrollment (Week 0) and End of Study (Week 16)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Sep 2024
  2. Study start1 Nov 2026 (estimated)
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Mixed methods
Masking
None (open label)
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06614543
Sponsor's protocol ID
HS26095 (B2023:073)
Status last verified
Sep 2026
First submitted
23 Sep 2024
Last updated
21 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual participant data (IPD) may be placed in a repository if required by a journal for publication purposes. De-identified IPD may also be requested from the principle investigator.

Questions about this trial

What is this clinical trial studying?

A study testing Supplemented Food in people with Weight Loss, run by University of Manitoba at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Kathy Cherepak, BSc (204-631-3834, kcherepak@sogh.mb.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Feasibility of incorporating the WI/CDIC supplemented foods into the WI weight loss clinic. (time frame: End of Study (Week 16)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in